<sup>225</sup>Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic
The widespread use of peptide receptor radionuclide therapy (PRRT) represents a major therapeutic breakthrough in nuclear medicine, particularly since the introduction of <sup>177</sup>Lu-radiolabeled somatostatin analogs. These radiopharmaceuticals have especially improved progression-f...
| Prif Awduron: | , , , , |
|---|---|
| Fformat: | Erthygl |
| Iaith: | English |
| Cyhoeddwyd: |
MDPI AG
2023-03-01
|
| Cyfres: | Pharmaceutics |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.mdpi.com/1999-4923/15/4/1051 |